Logo image of PCSA

PROCESSA PHARMACEUTICALS INC (PCSA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PCSA - US74275C3043 - Common Stock

0.259 USD
+0.01 (+3.02%)
Last: 11/28/2025, 7:54:24 PM
0.2653 USD
+0.01 (+2.43%)
After Hours: 11/28/2025, 7:54:24 PM
Fundamental Rating

2

Taking everything into account, PCSA scores 2 out of 10 in our fundamental rating. PCSA was compared to 192 industry peers in the Pharmaceuticals industry. While PCSA seems to be doing ok healthwise, there are quite some concerns on its profitability. PCSA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PCSA has reported negative net income.
PCSA had a negative operating cash flow in the past year.
PCSA had negative earnings in each of the past 5 years.
PCSA had a negative operating cash flow in each of the past 5 years.
PCSA Yearly Net Income VS EBIT VS OCF VS FCFPCSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of PCSA (-170.52%) is worse than 88.54% of its industry peers.
With a Return On Equity value of -221.71%, PCSA is not doing good in the industry: 74.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -170.52%
ROE -221.71%
ROIC N/A
ROA(3y)-293.98%
ROA(5y)-200.12%
ROE(3y)-432.49%
ROE(5y)-285.06%
ROIC(3y)N/A
ROIC(5y)N/A
PCSA Yearly ROA, ROE, ROICPCSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PCSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCSA Yearly Profit, Operating, Gross MarginsPCSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, PCSA has more shares outstanding
Compared to 5 years ago, PCSA has more shares outstanding
The debt/assets ratio for PCSA is higher compared to a year ago.
PCSA Yearly Shares OutstandingPCSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PCSA Yearly Total Debt VS Total AssetsPCSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

PCSA has an Altman-Z score of -17.86. This is a bad value and indicates that PCSA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PCSA (-17.86) is worse than 83.33% of its industry peers.
PCSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.86
ROIC/WACCN/A
WACCN/A
PCSA Yearly LT Debt VS Equity VS FCFPCSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

PCSA has a Current Ratio of 3.76. This indicates that PCSA is financially healthy and has no problem in meeting its short term obligations.
PCSA has a Current ratio (3.76) which is comparable to the rest of the industry.
PCSA has a Quick Ratio of 3.76. This indicates that PCSA is financially healthy and has no problem in meeting its short term obligations.
PCSA has a Quick ratio (3.76) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.76
Quick Ratio 3.76
PCSA Yearly Current Assets VS Current LiabilitesPCSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.96% over the past year.
EPS 1Y (TTM)71.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PCSA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 61.44% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88.2%
EPS Next 2Y39.27%
EPS Next 3Y24.54%
EPS Next 5Y61.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCSA Yearly Revenue VS EstimatesPCSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2027 2M 4M 6M
PCSA Yearly EPS VS EstimatesPCSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 -20 40 60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PCSA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PCSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCSA Price Earnings VS Forward Price EarningsPCSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCSA Per share dataPCSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PCSA's earnings are expected to grow with 24.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.27%
EPS Next 3Y24.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PCSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROCESSA PHARMACEUTICALS INC

NASDAQ:PCSA (11/28/2025, 7:54:24 PM)

After market: 0.2653 +0.01 (+2.43%)

0.259

+0.01 (+3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners0.74%
Inst Owner Change377.95%
Ins Owners0.92%
Ins Owner Change0%
Market Cap14.67M
Revenue(TTM)N/A
Net Income(TTM)-12.93M
Analysts80
Price Target1.02 (293.82%)
Short Float %20.44%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.83%
Min EPS beat(2)-6.56%
Max EPS beat(2)14.22%
EPS beat(4)3
Avg EPS beat(4)22.65%
Min EPS beat(4)-6.56%
Max EPS beat(4)61.8%
EPS beat(8)4
Avg EPS beat(8)11.52%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)10.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.51
P/tB 2.51
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -170.52%
ROE -221.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-293.98%
ROA(5y)-200.12%
ROE(3y)-432.49%
ROE(5y)-285.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.76
Quick Ratio 3.76
Altman-Z -17.86
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.2%
EPS Next Y88.2%
EPS Next 2Y39.27%
EPS Next 3Y24.54%
EPS Next 5Y61.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.21%
OCF growth 3YN/A
OCF growth 5YN/A

PROCESSA PHARMACEUTICALS INC / PCSA FAQ

What is the fundamental rating for PCSA stock?

ChartMill assigns a fundamental rating of 2 / 10 to PCSA.


What is the valuation status for PCSA stock?

ChartMill assigns a valuation rating of 1 / 10 to PROCESSA PHARMACEUTICALS INC (PCSA). This can be considered as Overvalued.


Can you provide the profitability details for PROCESSA PHARMACEUTICALS INC?

PROCESSA PHARMACEUTICALS INC (PCSA) has a profitability rating of 0 / 10.


Can you provide the financial health for PCSA stock?

The financial health rating of PROCESSA PHARMACEUTICALS INC (PCSA) is 5 / 10.